Opini贸n de los m茅dicos expertos en hipertensi贸n sobre las combinaciones triples en Espa帽a. Proyecto SINERGIA

详细信息	查看全文 | 推荐本文 |

• 作者：V. Barrios^a ; ^{vbarriosa@meditex.es} ; ^{vbarrios.hrc@salud.madrid.org} ; C. Calvo^b ; C. Suá ; rez^c ; M. De La Figuera^d ; C. Escobar^e ; G. Mu&#241 ; oz^f
• 关键词：Terapia combinada ; Opinió ; n de expertos ; Consenso ; Hipertensió ; n
• 刊名：Hipertensi贸n y Riesgo Vascular
• 出版年：2011
• 期刊代码：pca183_18891837
• 类别：med
• 出版时间：May-June 2011
• 卷：28
• 期：3
• 页码：83-90
• 文件大小：267 K

摘要

<h4 class="h4">Introductionh4>

The fixed triple combination therapy with valsartan-amlodipine-hydrochlorothiazide has been marketed recently in Spain.<h4 class="h4">Methodsh4>

The Sinergia project was initiated with the aim of improving knowledge on arterial hypertension through the sharing of the recent scientific evidence of combined therapies in the treatment of arterial hypertension and the review of the most recent recommendations of the most relevant national and international guidelines among the medical professionals. Special emphasis has placed on the importance of the use of the triple fixed combinations and specifically on the triple combination in a single tablet. For this purpose, 57 small group meetings were held with specialists in the field of hypertension known as 鈥渇ocus group鈥?all around Spain. These meetings made it possible to gather the opinion of 387 General Practitioners and 149 specialists.<h4 class="h4">Resultsh4>

In regards to efficacy, the most relevant aspect emphasized by the General Practitioners and specialists was that the drugs included in the triple combination have complementary action mechanisms. On the other hand, the fixed triple combination makes it possible to improve therapeutic compliance and treatment adherence. Finally, the triple combination has been shown to be safe, with a low rate of side effects.<h4 class="h4">Conclusionsh4>

The fixed triple combination of valsartan-amlodipine-hydrochlorothiazide is an effective and safe alternative in the treatment of patients who are not adequately controlled with two antihypertensive agents and those subjects who are taking three or more drugs with the aim of simplifying the treatment and improving adherence.